Press release content from Accesswire. The AP news staff was not involved in its creation. CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic April 19, 2021 GMT Review process started with submission of first CVnCoV data package TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 19, 2021 / The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland. The application for authorization was submitted to Swissmedic, the country’s authority responsible for the authorization and supervision of therapeutic products including vaccines.